Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.4450 (-0.32%) ($9.4450 - $9.4450) on Fri. Apr. 1, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.36% (three month average) | RSI | 64 | Latest Price | $9.4450(-0.32%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.8% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(63%) IWO(51%) IWM(48%) IWC(47%) IWN(44%) | Factors Impacting FOLD price | FOLD will decline at least -2.18% in a week (0% probabilities). VIXM(-26%) VXX(-12%) UUP(-10%) UNG(-9%) USO(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.18% (StdDev 4.36%) | Hourly BBV | -1 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $9.55(-1.1%) | 10 Day Moving Average | $9.52(-0.79%) | 20 Day Moving Average | $9.32(1.34%) | To recent high | -24.2% | To recent low | 19.8% | Market Cap | $2.439b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |